Get the Stockscreener App
68.04
0.60%
-0.41
After Hours:
68.00
-0.04
-0.06%
Corcept Therapeutics Inc stock is traded at $68.04, with a volume of 872.44K.
It is down -0.60% in the last 24 hours and up +31.71% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
See More
Previous Close:
$68.45
Open:
$68.11
24h Volume:
872.44K
Relative Volume:
0.98
Market Cap:
$7.13B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
54.00
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-2.66%
1M Performance:
+31.71%
6M Performance:
+98.89%
1Y Performance:
+208.99%
1-Day Range:
$67.41
$69.40
1-Week Range:
$64.66
$71.29
52-Week Range:
$20.84
$71.29
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
68.04 | 7.13B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Boston Trust Walden Corp Lowers Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Endogenous Cushing's Syndrome Market Statistics Expected - openPR
Corcept Therapeutics stock soars to all-time high of $70.78 - MSN
Market Recap Check: Corcept Therapeutics Inc (CORT)’s Positive Finish at 68.45, Up/Down 2.30 - The Dwinnex
Are Corcept Therapeutics Inc’shares a good deal? - US Post News
Investing in Corcept Therapeutics Inc (CORT): What You Must Know - Knox Daily
Calamos Advisors LLC Sells 4,908 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
KBC Group NV Acquires 1,296 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Q1 EPS Forecast for Corcept Therapeutics Lifted by Analyst - MarketBeat
Pacer Advisors Inc. Purchases 1,689 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Exchange Traded Concepts LLC Cuts Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Shares Down 5%Here's What Happened - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Blue Trust Inc. Buys 5,567 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Synergy Asset Management LLC Increases Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Q1 EPS Estimate for Corcept Therapeutics Boosted by Analyst - MarketBeat
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock? - MSN
SG Americas Securities LLC Has $564,000 Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Canaccord Genuity Group Forecasts Strong Price Appreciation for Corcept Therapeutics (NASDAQ:CORT) Stock - Defense World
Corcept Therapeutics stock soars to all-time high of $70.78 By Investing.com - Investing.com Australia
Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era - Yahoo Finance
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - Yahoo Finance
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy - MSN
Canaccord raises Corcept stock target to $130 on robust outlook By Investing.com - Investing.com Canada
Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Consensus Price Target from Analysts - Defense World
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue? - MSN
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Inspire Investing LLC Takes $807,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Zacks Research Issues Pessimistic Outlook for CORT Earnings - Defense World
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes" - MSN
Corcept Therapeutics (NASDAQ:CORT) Hits New 1-Year HighWhat's Next? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $62.34 - MSN
Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm - PR Newswire
Zacks Research Issues Negative Estimate for CORT Earnings - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.4%Should You Sell? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $62.34 By Investing.com - Investing.com Australia
Zacks Research Has Bullish Estimate for CORT Q4 Earnings - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Trading Up 7.9%Here's What Happened - MarketBeat
Corcept Therapeutics Generating Strong Revenue And Profit Growth (NASDAQ:CORT) - Seeking Alpha
Cushing's Syndrome Market Expected to Hit US$ 291.1 million - openPR
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT) - Insider Monkey
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):